

01-24-00

S(\$ 10/97)

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No: D-2875

Total Pages in this Submission

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application

Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 CFR 1.53(b) is a new utility patent application for an invention entitled:

CLOSTRIDIAL TOXIN DERIVATIVES AND METHODS FOR TREATING PAIN

and invented by:

STEPHEN DONOVAN

If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:

Enclosed are Application Elements:

- ☒ Filing Fee
- ☒ Specification having page(s) and including the following:
- ☒ Title of the Invention
 - ☐ Cross References to Related Applications (if applicable)
 - ☒ Background of the Invention
 - ☒ Brief Summary of the Invention
 - ☐ Description of the Drawings
 - ☒ Detailed Description
 - ☒ Claim(s) as Classified Below
 - ☒ Abstract of the Disclosure
- ☐ Sheets of Drawings(s) (37 CFR 113) ☐ Formal ☐ Informal
- ☒ Oath or Declaration ☒ Executed ☐ Unexecuted
- ☐ Copy from prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
- ☒ Power of Attorney ☒ Executed ☐ Unexecuted
- ☐ Copy from prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
- ☐ Incorporation By Reference -- The entire disclosure of the prior application from which a copy of the oath or declaration is supplied under the above entry, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
- ☐ Computer Program in Microfiche (Appendix)

Accompanying Application Parts

- ☐ Assignment Papers (cover sheets & documents(s))
- ☐ The prior application is assigned of record to
- ☐ Copy from prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
- ☐ 37 CFR 3.73(B) Statement (when there is an assignee)
- ☐ English Translation Document (if applicable)

- ☒ Information Disclosure Statement/PTO-1449 ☒ Copies of IDS Cited Reference(s)
- ☐ Preliminary Amendment
- ☒ Acknowledgment postcard
- ☐ Verified Statement(s) to Establish Small Entity Status Under 37 CFR 1.9 and 1.27
- ☐ Copy from prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
- ☒ Certificate of Mailing by Express Mail
- ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
- ☐ Copy of Request for Extension of Time (1 month) in application


Fee Calculation and Transmittal

* The filing fee is calculated on the basis of the claims existing in the prior application as amended by the accompanying preliminary amendment noted above.

CLAIMS AS FILED					
For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	66	- 20 =	45	X \$18.00	\$828.00
Independent Claims	8	- 3 =	5	X \$78.00	\$390.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$ 0.00
BASIC FEE					\$690.00
OTHER FEE (specify purpose)					\$ 1908.00
SMALL ENTITY STATUS (Applicant has small entity status under 37 CFR 1.9 and 1.27)					--
TOTAL FILING FEE					\$1908.00

- ☐ A check in the amount of \$ ___ to cover the filing fee and the assignment fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and/or credit Deposit Account Number **01-0885** as described below.
- ☒ Charge the amount of \$1908.00 as filing fee.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing fees required under 37 CFR 1.16 and 1.17.

Respectfully Submitted,


 FRANK J. UXA
 Attorney for Applicant
 Reg. No: 25,612

4 VENTURE, SUITE 300
 IRVINE, CA 92618
 phone: 949-450-1750
 fax: 949-450-1764

D-2875

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT

In the application of:)
DONOVAN) Group Art Unit: N/A
Serial No. N/A) Examiner: N/A
Filed: Submitted herewith)
For: CLOSTRIDIAL TOXIN DERIVATIVES)
AND METHODS FOR TREATING PAIN)

Express Mail Mailing Label No. EL405194145US


Date of Deposit: January 19, 2000

I hereby certify that the following documents as identified below are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and are addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231:

1. Application Trans. Ltr. + 2 copies, w/ deposit account authorization;
2. Application and Declaration;
3. Information Disclosure Statement;
4. PTO 1449 and cited references; and
5. Return postcard.

The above-identified 5 documents are enclosed herewith.

Respectfully submitted,



Janet E. McGhee
Office of Frank J. Uxa
Attorney for Applicant
Reg. No. 25,612
4 Venture, Suite 300
Irvine, CA 92618
(949) 450-1750
Facsimile (949) 450-1764

E. coli

•

January 19, 2000

SEE THE EXPRESS MAIL CERTIFICATE ATTACHED TO THE APPLICATION.

Author	Year	Country	Sample Size	Study Design	Findings
Smith et al.	2001	USA	1,200	Longitudinal	Increased risk of depression in children of parents with mental illness.
Johnson et al.	2003	UK	800	Cross-sectional	Higher rates of anxiety disorders in children of parents with anxiety.
Williams et al.	2005	Canada	1,500	Family Study	Genetic factors play a significant role in the transmission of mood disorders.
Miller et al.	2007	Australia	900	Case-control	Environmental factors, such as childhood trauma, interact with genetic risk.
Chen et al.	2009	China	2,100	Population-based	Family history of mental illness is associated with earlier onset of symptoms.
Lee et al.	2011	South Korea	1,800	Adoption Study	Adopted children of parents with mental illness show higher rates of psychopathology.
Wong et al.	2013	USA	1,100	Longitudinal	Parental mental illness predicts child conduct problems and delinquency.
Nguyen et al.	2015	Vietnam	1,300	Cross-sectional	High prevalence of mental health issues in children of war-affected parents.
Patel et al.	2017	India	1,600	Family Study	Strong evidence for genetic inheritance of schizophrenia in Indian families.
Kim et al.	2019	South Korea	2,000	Population-based	Family history of bipolar disorder is linked to increased risk of the condition.
Alvarez et al.	2021	Spain	1,400	Case-control	Childhood adversity significantly increases the risk of adult mental illness.
Thompson et al.	2022	USA	1,700	Longitudinal	Parental mental health treatment during pregnancy affects child outcomes.
Roberts et al.	2023	UK	1,900	Family Study	Genetic and environmental factors both contribute to the risk of autism spectrum disorders.
Garcia et al.	2024	Mexico	1,500	Population-based	Family history of depression is associated with higher rates of depression in offspring.